Insulin is almost universally discussed as a metabolic hormone, a signal that regulates blood glucose by instructing cells to absorb it from the bloodstream. In popular understanding, insulin lives in the domain of diabetes and dietary carbohydrates, not in the domain of memory and attention. This framing is not wrong, but it is severely incomplete. The brain is one of the most densely insulin-receptive organs in the body, with particularly high receptor concentrations in the hippocampus and prefrontal cortex, the exact regions most central to memory formation and executive function.
Insulin in the brain does not primarily regulate energy uptake the way it does in muscle and fat. It regulates synaptic plasticity, neurogenesis, the survival of neurons, and the activity of dopaminergic and cholinergic systems that underpin focused attention and motivated cognition. When central insulin signaling works well, it is a quiet enabler of sharp memory and sustained focus. When it is impaired, through what is increasingly recognized as central insulin resistance, the cognitive consequences are measurable, progressive, and, left unaddressed, potentially irreversible.
Here we trace how insulin moves from its familiar metabolic role into the unfamiliar but scientifically well-established territory of cognitive neuroscience, and what the growing understanding of central insulin resistance means for anyone who cares about maintaining sharpness across a lifetime.
Contents
Insulin Receptors in the Brain: Not What You Expected
The discovery that the brain is richly populated with insulin receptors, reported in detailed studies from the 1970s and 1980s by researchers including Jesse Roth and Candace Pert, was initially puzzling precisely because neurons were thought not to require insulin for glucose uptake. Unlike peripheral tissues, neurons express GLUT3 transporters that take up glucose independently of insulin, so the insulin receptors in the brain could not be explained by the same logic that explained their presence in muscle and liver.
Subsequent research established that central insulin signaling operates through a fundamentally different set of functions from peripheral insulin signaling, even though many of the same molecular pathways are involved. The insulin receptor in the brain activates the PI3K/Akt signaling cascade and the MAPK pathway, which regulate not glucose uptake but protein synthesis, cell survival, synaptic remodeling, and the trafficking of neurotransmitter receptors to the synapse. In the hippocampus specifically, insulin signaling promotes the insertion of AMPA receptors into the postsynaptic density, directly facilitating long-term potentiation, the cellular mechanism of memory encoding. It also stimulates neurogenesis in the dentate gyrus, the hippocampal subregion where new neurons continue to be born throughout adult life and where neurogenesis is now understood to support the encoding of distinct episodic memories.
Insulin and the Cholinergic System
Beyond hippocampal plasticity, insulin signaling in the basal forebrain modulates the cholinergic neurons that project widely to the cortex and hippocampus and that are central to the sustained attention and working memory that focused cognitive performance requires. The basal forebrain cholinergic system, discussed in the context of memory and attention throughout this series, is significantly regulated by insulin. Research by Suzanne Craft and colleagues at Wake Forest School of Medicine demonstrated that intranasally administered insulin, which bypasses peripheral metabolism and delivers insulin directly to the brain, improves memory performance and attention in both healthy older adults and individuals with mild cognitive impairment, effects that are most pronounced in people with impaired peripheral insulin sensitivity suggesting that the brain’s insulin signaling had already been compromised.
The cholinergic connection is particularly important because it explains how central insulin resistance can produce cognitive effects that look superficially like cholinergic deficiency, including reduced working memory capacity, impaired sustained attention, and difficulty encoding new information, without there being any primary defect in acetylcholine synthesis or release. The defect is upstream, in the insulin signaling that should be sustaining cholinergic tone.
Central Insulin Resistance: The Brain’s Own Metabolic Problem
Peripheral insulin resistance, in which skeletal muscle, liver, and fat cells respond inadequately to insulin signaling, is familiar as the pathophysiology of type 2 diabetes and metabolic syndrome. Less well appreciated is that the brain can develop insulin resistance largely independently of peripheral tissues, though the conditions that promote peripheral insulin resistance, including chronic overnutrition, sedentary behavior, sleep deprivation, and systemic inflammation, also promote central insulin resistance.
Central insulin resistance in the brain involves the downregulation or desensitization of insulin receptors in the hippocampus and prefrontal cortex, impaired activation of the downstream PI3K/Akt signaling cascade, and reduced responsiveness of synaptic plasticity mechanisms to insulin’s trophic signals. The net effect is that even when circulating insulin levels are normal or elevated, the brain’s neurons are not receiving or responding to insulin’s neuroplasticity-promoting signals effectively. This creates a form of cognitive deprivation that is invisible to standard metabolic blood tests because the problem lies in neural receptor sensitivity, not in circulating hormone concentration.
The Alzheimer’s Disease Connection
The relationship between insulin resistance and cognitive decline has been most extensively studied in the context of Alzheimer’s disease, and the findings are striking enough that, as briefly mentioned in the glucose article, some researchers have proposed calling Alzheimer’s “type 3 diabetes.” While this framing remains contested, the underlying evidence for the insulin resistance-Alzheimer’s connection is substantial and mechanistically specific.
People with type 2 diabetes have approximately twice the risk of developing Alzheimer’s disease compared to matched controls without diabetes. Postmortem studies of Alzheimer’s brains consistently find reduced insulin receptor expression and impaired insulin signaling in the hippocampus, independent of peripheral diabetic status. Insulin signaling deficiency in the brain promotes the pathological phosphorylation of tau protein and the impaired clearance of amyloid-beta peptides, both of which are central to Alzheimer’s pathology. The enzyme insulin-degrading enzyme (IDE), which is responsible for breaking down insulin in the brain, also degrades amyloid-beta; when the brain is chronically flooded with insulin due to peripheral hyperinsulinemia (a common consequence of insulin resistance), IDE becomes occupied with insulin clearance, leaving amyloid-beta less efficiently cleared. This is one mechanistic pathway through which peripheral metabolic dysregulation may contribute directly to the pathological accumulation associated with neurodegeneration.
The Insulin-BDNF Axis
One of the most significant downstream consequences of impaired central insulin signaling is reduced production of brain-derived neurotrophic factor (BDNF), the protein that supports neuronal survival, promotes synaptic plasticity, and stimulates neurogenesis in the hippocampus. BDNF is sometimes called the brain’s growth hormone, and its concentration in the hippocampus is among the best-studied predictors of memory performance and resistance to cognitive decline. Insulin signaling in hippocampal neurons is a significant upstream driver of BDNF expression, and central insulin resistance reduces BDNF production through the same PI3K/Akt pathway impairments that reduce synaptic plasticity directly.
The insulin-BDNF axis is also where exercise intersects with insulin sensitivity in a particularly compelling way. Aerobic exercise both improves insulin sensitivity and independently upregulates BDNF production through multiple additional pathways including the exercise-induced release of lactate, irisin, and other muscle-derived factors that cross the blood-brain barrier. This convergence explains part of why exercise has such robust and consistent effects on memory and cognitive aging: it repairs and reinforces the insulin-BDNF signaling axis that central insulin resistance progressively degrades.
Practical Paths to Better Central Insulin Signaling
The evidence on improving central insulin sensitivity to support memory and focus points in several directions, each well-supported by mechanistic and clinical research. Aerobic exercise is the most potent single intervention, improving both peripheral and central insulin sensitivity through multiple pathways while simultaneously upregulating BDNF and reducing the neuroinflammation that exacerbates insulin resistance. The cognitive benefits of exercise documented throughout this series are substantially mediated through its effects on insulin signaling.
Dietary patterns that minimize persistent hyperinsulinemia, including reducing high-glycemic load, prioritizing fiber and protein at meals, and considering time-restricted eating or intermittent fasting, reduce the chronic insulin signaling load that desensitizes central receptors over time. These interventions do not eliminate insulin but normalize the pattern of its release in ways that give receptors time to resensitize between meals.
Sleep quality has a direct and rapidly measurable effect on insulin sensitivity: even a single night of poor sleep produces measurable peripheral insulin resistance the following morning, and the central effects are likely parallel. Managing sleep as a non-negotiable component of metabolic and cognitive health is therefore as much an insulin-sensitivity strategy as a fatigue management strategy.
At the targeted supplementation level, several compounds have evidence for supporting central insulin signaling specifically. Berberine activates AMPK, a cellular energy sensor that improves insulin sensitivity through pathways that partially overlap with metformin. Alpha-lipoic acid, discussed in the mitochondrial article, improves insulin receptor sensitivity partly through its antioxidant activity in reducing the oxidative stress that contributes to receptor desensitization. Magnesium, essential for hundreds of enzymatic reactions including those in the insulin signaling cascade, is deficient in a significant proportion of the general population and its supplementation has been associated with improved insulin sensitivity in multiple trials. Well-designed nootropic formulations that address both the neurotransmitter and metabolic dimensions of cognition will increasingly reflect this insulin-sensitivity research, as the field moves toward a more integrated understanding of how metabolic health at the cellular level underpins every cognitive function that has been discussed across this series.